BioRestorative Therapies Signs Five-Year Supply Agreement With Cartessa; BioRestorative To Supply Cartessa With Finished Vials Of Commercial Product Sold Under Chronos ExoCR Brand
Portfolio Pulse from Benzinga Newsdesk
BioRestorative Therapies has signed a five-year supply agreement with Cartessa. Under this agreement, BioRestorative will supply Cartessa with finished vials of commercial product sold under the Chronos ExoCR brand.

May 15, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioRestorative Therapies has entered into a five-year supply agreement with Cartessa, which is expected to positively impact its revenue and market presence.
The long-term supply agreement with Cartessa is likely to enhance BioRestorative's revenue streams and market presence, leading to a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100